Tuberculous Drug-induced Liver Injury and Treatment Re-challenge in Human Immunodeficiency Virus Co-infection

BACKGROUND: Tuberculosis drug-induced liver injury (TB-DILI) is the most common adverse event necessitating therapy interruption. The optimal re-challenge strategy for antituberculous therapy (ATT) remains unclear, especially in human immunodeficiency virus (HIV) co-infected individuals in high-prev...

Descripción completa

Detalles Bibliográficos
Autores principales: Costiniuk, Cecilia T., Gosnell, Bernadett I., Manzini, Thandekile C., Du Plessis, Camille N., Moosa, Mahomed Yunus S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693306/
https://www.ncbi.nlm.nih.gov/pubmed/26752869
http://dx.doi.org/10.4103/0974-777X.170499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693306/
https://www.ncbi.nlm.nih.gov/pubmed/26752869
http://dx.doi.org/10.4103/0974-777X.170499

Ejemplares similares